Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Medpace Holdings Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.78, while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | MEDP | |
|---|---|---|
52-Week High | $112.91 | $620.59 |
52-Week Low | $106.96 | $308.88 |
Market Cap | — | $15.08B |
Sector | — | Technology |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% on the day, with technical indicators showing a bearish trend from moving averages while oscillators are neutral. The ETF maintains a consistent dividend schedule, with recent payments around $0.40-0.42 per share. Market sentiment is mixed amid Federal Reserve uncertainty and shifting bond flows.
The outlook for LQD hinges on interest rate direction and corporate bond demand. Opportunities exist for income-focused investors seeking investment-grade exposure, but risks include potential Fed rate hikes and economic volatility that could pressure bond prices. Current technical weakness suggests cautious near-term positioning.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
